JP2002511431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002511431A5 JP2002511431A5 JP2000543171A JP2000543171A JP2002511431A5 JP 2002511431 A5 JP2002511431 A5 JP 2002511431A5 JP 2000543171 A JP2000543171 A JP 2000543171A JP 2000543171 A JP2000543171 A JP 2000543171A JP 2002511431 A5 JP2002511431 A5 JP 2002511431A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- αgal
- composition
- cross
- heterologous antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000642 polymer Polymers 0.000 description 74
- 238000000034 method Methods 0.000 description 23
- 101000718529 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Alpha-galactosidase Proteins 0.000 description 19
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 239000000427 antigen Substances 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 125000000524 functional group Chemical group 0.000 description 16
- 238000006880 cross-coupling reaction Methods 0.000 description 9
- 150000002482 oligosaccharides Chemical class 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 7
- 108010005774 beta-Galactosidase Proteins 0.000 description 7
- 229920006037 cross link polymer Polymers 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000001350 alkyl halides Chemical class 0.000 description 5
- 239000003431 cross linking reagent Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000000269 nucleophilic effect Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 230000019970 B cell anergy Effects 0.000 description 1
- 239000007848 Bronsted acid Substances 0.000 description 1
- 239000003341 Bronsted base Substances 0.000 description 1
- 102000030902 Galactosyltransferase Human genes 0.000 description 1
- 108060003306 Galactosyltransferase Proteins 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 239000002879 Lewis base Substances 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Chemical group 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical group N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 150000007527 lewis bases Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010452 phosphate Chemical group 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- -1 phosphoryl halide Chemical class 0.000 description 1
- 150000003958 selenols Chemical class 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6052598A | 1998-04-15 | 1998-04-15 | |
| US09/060,525 | 1998-04-15 | ||
| PCT/US1999/008326 WO1999052561A1 (en) | 1998-04-15 | 1999-04-15 | Inhibition of xenoreactive antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002511431A JP2002511431A (ja) | 2002-04-16 |
| JP2002511431A5 true JP2002511431A5 (https=) | 2006-06-08 |
Family
ID=22030043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000543171A Pending JP2002511431A (ja) | 1998-04-15 | 1999-04-15 | 異種反応性抗体の阻害 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6572867B1 (https=) |
| EP (1) | EP1087791B1 (https=) |
| JP (1) | JP2002511431A (https=) |
| AT (1) | ATE304865T1 (https=) |
| AU (1) | AU761831B2 (https=) |
| CA (1) | CA2326618A1 (https=) |
| DE (2) | DE69927369T2 (https=) |
| ES (1) | ES2249890T3 (https=) |
| WO (1) | WO1999052561A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399578B1 (en) * | 1998-12-09 | 2002-06-04 | La Jolla Pharmaceutical Company | Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same |
| JP2002531531A (ja) * | 1998-12-09 | 2002-09-24 | ラ ホヤ ファーマシューティカル カンパニー | 循環している抗体を減少させるための方法および処方物 |
| EP1257558A1 (en) * | 2000-01-13 | 2002-11-20 | Alchemia Pty Ltd | Methods for synthesis of alpha-d-gal (1- 3) gal-containing oligosaccharides |
| US7270961B2 (en) * | 2002-04-16 | 2007-09-18 | Hui Sunny Chang | In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes |
| US20060078534A1 (en) * | 2004-10-13 | 2006-04-13 | Dominique Charmot | Toxin binding compositions |
| US20060099169A1 (en) * | 2004-10-13 | 2006-05-11 | Ilypsa, Inc. | Toxin binding compositions |
| FR2886298A1 (fr) * | 2005-05-24 | 2006-12-01 | Ifremer | Anticorps ou fragment d'anticorps couple a un agent immunogene |
| WO2008101177A2 (en) * | 2007-02-16 | 2008-08-21 | University Of Virginia Patent Foundation | Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis |
| EP2095829A1 (en) * | 2008-02-27 | 2009-09-02 | LEK Pharmaceuticals D.D. | Selenium containing modifying agents and conjugates |
| US9891219B2 (en) * | 2008-10-10 | 2018-02-13 | Mayo Foundation For Medical Education And Research | Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive |
| US9420770B2 (en) | 2009-12-01 | 2016-08-23 | Indiana University Research & Technology Corporation | Methods of modulating thrombocytopenia and modified transgenic pigs |
| WO2011139488A2 (en) | 2010-05-06 | 2011-11-10 | Mayo Foundation For Medical Education And Research | Methods and materials for reducing cardiac xenograft rejection |
| US20130149331A1 (en) * | 2011-05-03 | 2013-06-13 | Peng George Wang | Rhamnose and forssman conjugated immunogenic agents |
| US9533214B2 (en) | 2012-09-25 | 2017-01-03 | Igt | Gaming system and method for providing plays of multiple games |
| US9994605B2 (en) | 2014-03-13 | 2018-06-12 | Universitaet Basel | Carbohydrate ligands that bind to IgM antibodies against myelin-associated glycoprotein |
| EP2987503A1 (en) * | 2014-08-22 | 2016-02-24 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Methods and reagents for prevention and/or treatment of infection |
| CA2965550A1 (en) | 2014-10-22 | 2016-04-28 | Indiana University Research & Technology Corporation | Triple transgenic pigs suitable for xenograft |
| CA2996073A1 (en) | 2015-09-16 | 2017-03-23 | Universitat Basel | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids |
| WO2021234676A1 (en) | 2020-05-22 | 2021-11-25 | Aab Therapeutics, Llc | Compounds and methods for suppressing an immune response to substances containing polyethylene glycol |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8001748L (sv) * | 1980-03-05 | 1981-09-06 | Kaellenius Gunilla | Kompositioner for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutik |
| US5126131A (en) * | 1983-01-24 | 1992-06-30 | The Johns Hopkins University | Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates. |
| US5268454A (en) * | 1991-02-08 | 1993-12-07 | La Jolla Pharmaceutical Company | Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier |
| US5219564A (en) * | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
| US5191066A (en) * | 1990-12-07 | 1993-03-02 | Abbott Laboratories | Site-specific conjugation of immunoglobulins and detectable labels |
| WO1993003735A1 (en) * | 1991-08-23 | 1993-03-04 | Alberta Research Council | Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients |
| GB9202219D0 (en) * | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
| AU2158995A (en) * | 1994-03-15 | 1995-10-03 | Medical College Of Pennsylvania And Hahnemann University | Compositions and methods for vaccines comprising alpha-galactosyl epitopes |
| US5866135A (en) * | 1994-04-21 | 1999-02-02 | North American Vaccine, Inc. | Group A streptococcal polysaccharide immunogenic compositions and methods |
| AU1404597A (en) * | 1995-12-21 | 1997-07-17 | Procur Ab | Galactopyranosides and their use |
| WO1998033528A2 (en) * | 1997-02-05 | 1998-08-06 | Biotransplant, Inc. | Induction of b cell tolerance |
| US6676946B2 (en) * | 1997-03-27 | 2004-01-13 | Institut Pasteur | Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof |
| PT970114E (pt) * | 1997-04-18 | 2006-12-29 | Novartis Ag | Neoglicoproteínas |
| US6096725A (en) * | 1997-07-02 | 2000-08-01 | Neose Technologies, Inc. | Methods of using αGal oligosaccharides as immune system targeting agents |
-
1999
- 1999-04-15 AU AU35645/99A patent/AU761831B2/en not_active Ceased
- 1999-04-15 DE DE69927369T patent/DE69927369T2/de not_active Expired - Fee Related
- 1999-04-15 JP JP2000543171A patent/JP2002511431A/ja active Pending
- 1999-04-15 US US09/292,153 patent/US6572867B1/en not_active Expired - Fee Related
- 1999-04-15 ES ES99917553T patent/ES2249890T3/es not_active Expired - Lifetime
- 1999-04-15 DE DE1087791T patent/DE1087791T1/de active Pending
- 1999-04-15 WO PCT/US1999/008326 patent/WO1999052561A1/en not_active Ceased
- 1999-04-15 CA CA002326618A patent/CA2326618A1/en not_active Abandoned
- 1999-04-15 AT AT99917553T patent/ATE304865T1/de not_active IP Right Cessation
- 1999-04-15 EP EP99917553A patent/EP1087791B1/en not_active Expired - Lifetime
-
2003
- 2003-03-28 US US10/402,845 patent/US20040141944A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/932,737 patent/US20080124396A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002511431A5 (https=) | ||
| ES2404685T3 (es) | Derivados heterobifuncionales de poli(etilenglicol) y métodos para su preparación | |
| EP0955064B1 (en) | Process for producing drug complexes | |
| US11446238B2 (en) | Injectable dendrimer hydrogel nanoparticles | |
| US7196073B2 (en) | Imine-forming polysaccharide adjuvants and immunostimulants | |
| JP2002513028A (ja) | ポリサッカリド抗原結合体 | |
| US6150341A (en) | Vitamin B12 derivatives and methods for their preparation | |
| JP4248189B2 (ja) | ホスホリルコリン基含有多糖類及びその製造方法 | |
| WO2002040058A2 (en) | Hydroxyapatite-targeting poly(ethylene glycol) and related polymers | |
| CZ308395A3 (en) | Complex for b12 vitamin reception, process of its preparation, compositions containing thereof and its use | |
| JPWO1997046261A1 (ja) | 薬物複合体の製造方法 | |
| JPWO1997046260A1 (ja) | 薬物複合体 | |
| JPH06256222A (ja) | ポリエチレンオキシド改質プロテイン及びポリペプチドのシクロデキストリンとの凍結乾燥複合体 | |
| US5738864A (en) | Drug delivery agents incorporating mitomycin | |
| HU182011B (en) | Process for producing new antigene derivatives and pharmaceutical compositions containing them | |
| EP1263472A2 (en) | Modification of biopolymers for improved drug delivery | |
| AU772167B2 (en) | Polypeptide dendrimers as unimolecular carriers of diagnostic imaging contrast agents, bioactive substances and drugs | |
| US7408075B1 (en) | Synthesis of phosphocholine ester derivatives and conjugates thereof | |
| EP1574217A1 (en) | Imine-forming polysaccharides, preparation thereof and the use thereof as adjuvants and immunostimulants |